Repository logo
 
Publication

Systematic review and evidence gap mapping of biomarkers associated with neurological manifestations in patients with COVID-19

2024-01Journal article Open access
Simple item page
dc.contributor.authorDomingues, K. Z.
dc.contributor.authorCobre, A. F.
dc.contributor.authorLazo, R. E.
dc.contributor.authorAmaral, L. S.
dc.contributor.authorFerreira, L. M.
dc.contributor.authorTonin, Fernanda
dc.contributor.authorPontarolo, R.
dc.date.accessioned2023-12-08T11:57:12Z
dc.date.available2023-12-08T11:57:12Z
dc.date.issued2024-01
dc.description.abstractObjective: This study aimed to synthesize the existing evidence on biomarkers related to coronavirus disease 2019 (COVID-19) patients who presented neurological events. Methods: A systematic review of observational studies (any design) following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines and the Cochrane Collaboration recommendations was performed (PROSPERO: CRD42021266995). Searches were conducted in PubMed and Scopus (updated April 2023). The methodological quality of nonrandomized studies was assessed using the Newcastle‒Ottawa Scale (NOS). An evidence gap map was built considering the reported biomarkers and NOS results. Results: Nine specific markers of glial activation and neuronal injury were mapped from 35 studies published between 2020 and 2023. A total of 2,237 adult patients were evaluated in the included studies, especially during the acute phase of COVID-19. Neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) biomarkers were the most frequently assessed (n = 27 studies, 77%, and n = 14 studies, 40%, respectively). Although these biomarkers were found to be correlated with disease severity and worse outcomes in the acute phase in several studies (p < 0.05), they were not necessarily associated with neurological events. Overall, 12 studies (34%) were judged as having low methodological quality, 9 (26%) had moderate quality, and 9 (26%) had high quality. Conclusions: Different neurological biomarkers in neurosymptomatic COVID-19 patients were identified in observational studies. Although the evidence is still scarce and conflicting for some biomarkers, well-designed longitudinal studies should further explore the pathophysiological role of NfL, GFAP, and tau protein and their potential use for COVID-19 diagnosis and management.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationDomingues KZ, Cobre AF, Lazo RE, Amaral LS, Ferreira LM, Tonin FS, et al. Systematic review and evidence gap mapping of biomarkers associated with neurological manifestations in patients with COVID-19. J Neurol. 2024;271:1-23.pt_PT
dc.identifier.doi10.1007/s00415-023-12090-6pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.21/16650
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherSpringerpt_PT
dc.relation.publisherversionhttps://link.springer.com/article/10.1007/s00415-023-12090-6pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/pt_PT
dc.subjectCOVID-19pt_PT
dc.subjectSARS-CoV-2pt_PT
dc.subjectNeurologicalpt_PT
dc.subjectBiomarkerpt_PT
dc.subjectNeuroflament light chainpt_PT
dc.subjectTau proteinpt_PT
dc.titleSystematic review and evidence gap mapping of biomarkers associated with neurological manifestations in patients with COVID-19pt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage23pt_PT
oaire.citation.startPage1pt_PT
oaire.citation.titleJournal of Neurologypt_PT
oaire.citation.volume271pt_PT
person.familyNameTonin
person.givenNameFernanda
person.identifier.ciencia-idD01C-C700-9411
person.identifier.orcid0000-0003-4262-8608
person.identifier.ridO-2050-2017
person.identifier.scopus-author-id56085115800
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication61ded30e-ecec-4b3e-b953-2293e080ebdd
relation.isAuthorOfPublication.latestForDiscovery61ded30e-ecec-4b3e-b953-2293e080ebdd

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Systematic review and evidence gap mapping of biomarkers associated with neurological manifestations in patients with COVID-19.pdf
Size:
921.76 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

ESTeSL - Artigos